Description
YK-4-279 is an Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. At 10 µM, YK-4-279 blocks RHA binding to ES-FLI1 and induces apoptosis of a panel of Ewing’s sarcoma tumor cell lines with IC₅₀ values ranging from 0.5-2 µM. At 1.5 mg per dose, YK-4-279 reduces the growth of Ewing’s sarcoma orthotopic xenografts in mice after treatment with the inhibitor for two weeks.
YK-4-279 is an Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. At 10 µM, YK-4-279 blocks RHA binding to ES-FLI1 and induces apoptosis of a panel of Ewing’s sarcoma tumor cell lines with IC₅₀ values ranging from 0.5-2 µM.
Alternate Name/Synonyms: 4,7-Dichloro-1,3-dihydro-3-hydroxy-3-[2-(4-methoxyphenyl)-2-oxoethyl]-2H-indol-2-one
Appearance: White solid
Formulation: N/A
CAS Number: 1037184-44-3
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₇H₁₃Cl₂NO₄
Molecular Weight: 366.2
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>30 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: An Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1
MDL Number: N/A
PubChem CID: 44632017
SMILES: COC1=CC=C(C=C1)C(=O)CC2(C3=C(C=CC(=C3NC2=O)Cl)Cl)O
InChi: InChI=1S/C17H13Cl2NO4/c1-24-10-4-2-9(3-5-10)13(21)8-17(23)14-11(18)6-7-12(19)15(14)20-16(17)22/h2-7,23H,8H2,1H3,(H,20,22)
InChi Key: HLXSCTYHLQHQDJ-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |